Risks associated with precocious puberty might be observed in the rapidly progressive form of borderline early puberty (BEP). Differentiating the rate of progression is important for deciding treatment with gonadotropin-releasing hormone analogue (GnRHa). The aim was to examine the treatment characteristics and effect of treatment on predicted adult height (PAH).
Retrospective observational study.
Single-center, a pediatric endocrinology unit.
A total of 135 girls, pubertal findings starting between 7-10 years of age.
Data were collected via chart review. Patient groups were defined as treated with GnRHa (n = 63) or untreated (n = 72) girls.
Main Outcome Measures
Referral characteristics and anthropometric and pubertal findings of the patients with BEP, effect of treatment on PAH, and final height of the groups were compared.
The mean (±SD) age of the patients at admission and for the first appearence of pubertal findings was 8.8 ± 1.0 and 8.0 ± 0.8 years, respectively. Target height and PAH-target height values at admission were similar. At initiation of treatment, PAH of the treated girls (157.8 ± 7.2 cm) were significantly lower compared with untreated girls (160.7 ± 6.5 cm). The age at menarche of patients in the treated and untreated groups were 12.3 ± 1.0 and 11.3 ± 1.1 years, respectively. The final height of the groups were similar (157.1 ± 6.6 vs 157.0 ± 5.9 cm; P = .922) despite a lower PAH of the treated group.
GnRHa treatment resulted in an increase in PAH and normalized the age of menarche in patients with BEP. In selected girls with rapidly progressive BEP, GnRHa treatment may be considered.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Journal of Pediatric and Adolescent Gynecology
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Puberty and its disorders in the female.in: Sperling M.A. Pediatric Endocrinology. 4th ed. Elsevier Saunders, Philadelphia2014: 569-663
- The timing of normal puberty and the age limits of sexual precocity: variations around the world, secular trends and changes after migration.Endocr Rev. 2003; 24: 668
- Puberty and pubertal growth in healthy Turkish girls: no evidence for secular trend.J Clin Res Pediatr Endocrinol. 2008; 1: 8
- Early puberty in girls.Best Pract Res Clin Endocrinol Metab. 2002; 16: 153
- Auxological and biochemical evaluation of pubertal suppression wit the GnRH agonist leuprolide acetate in early and precocious puberty.Horm Res. 1999; 51: 270
- Lack of effect of GnRH agonists on final height in girls with advanced puberty: a randomized long-term pilot study.J Clin Endocrinol Metab. 1999; 84: 3575
- Randomised trial of LHRH analogue treatment on final height in girls with onset of puberty aged 7.5-8.5 years.Arch Dis Child. 1999; 81: 329
- Management of central isosexual precocity: diagnosis, treatment, outcome.Curr Opin Pediatr. 2000; 12: 394
- Reexamination of the age limit for defining when puberty is precocious in girls in the United States: implications for evaluation and treatment.Pediatrics. 1999; 104: 93
- Unsustained or slowly progressive puberty in young girls: ınitial presentation and long-term follow-up of 20 untreated patients.J Clin Endocrinol Metab. 1999; 84: 415
- Accelerated versus slowly progressive forms of puberty in girls with precocious and early puberty. Gonadotropin suppressive effect and final height obtained with two different analogs.J Pediatr Endocrinol Metab. 2004; 17: 759
- Consensus statement on the use of gonadotropin-releasing hormone analogs in children.Pediatrics. 2009; 123: e752
- Central precocious puberty: update on diagnosis and treatment.Paediatr Drugs. 2015; 17: 273
- Clinical review 60: effects of gonadotrophin-releasing hormone analogue therapy on adult stature in precocious puberty.J Clin Endocrinol Metab. 1994; 79: 331
- Adult height in girls with idiopathic true precocious puberty.J Clin Endocrinol Metab. 1994; 79: 415
- Girls with early puberty attain a near- final height similar to their target height.J Pediatr Endocrinol Metab. 2011; 24: 339
- Adult height after spontaneous pubertal growth or GnRH analog treatment in girls with early puberty: a meta analysis.Eur J Pediatr. 2017; 176: 697
- Precocious puberty and statural growth.Hum Reprod Update. 2004; 10: 135
- Body weight, length and head circumference at birth in a cohort of Turkish newborns.J Clin Res Pediatr Endocrinol. 2012; 4: 132
- Growth references for Turkish children aged 6 to 18 years.Acta Paediatr. 2006; 95: 1635
- Body mass index references for Turkish children.Acta Paediatr. 2006; 95: 194
- High dose recombinant human GH treatment of GH-deficient patients in puberty increases near final-height:a randomized, multicenter trial. Genentech, Inc., Cooperative Study Group.J Clin Endocrinol Metab. 2000; 85: 3653
- Normal ranges for immunochemiluminometric gonadotropin assays.J Pediatr. 1995; 127: 40
- Ultrasonographic and clinical parameters for early differentiation between precocious puberty and premature thelarche.Eur J Endocrinol. 2006; 154: 891
- Growth, bone maturation and height prediction after three years of therapy with the slow release GnRH-agonist Decapeptly – depot in children with central precocious puberty.Horm Metab Res. 1992; 24: 122
- Analysis of the factors affecting auxological response to GnRH agonist treatment and final height outcome in girls with idiopathic central precocious puberty.Eur J Endocrinol. 1999; 141: 140
- Gonadotropin-suppressive therapy in girls with early and fast puberty affects the pace of puberty but not total pubertal growth or final height.J Clin Endocrinol Metab. 2002; 87: 2090
- Metabolic control of female puberty: potential therapeutic targets.Expert Opin Ther Targets. 2016; 20: 1181
- Obesity and the pubertal transition in girls and boys.Reproduction. 2010; 140: 399
- Early sexual maturation, central adiposity and subsequent overweight in late adolescence. A four-year follow up of 1605 adolescent Norwegian boys and girls: the Young Hunt study.BMC Public Health. 2007; 12: 7
- Investigating the relationship between precocious puberty and obesity: a cross- sectional study in Shanghai, China.BMJ Open. 2017; 11: 7
- Puberty and prenatal growth.Mol Cell Endocrinol. 2006; 254-5: 22
- Age at menarche: influences of prenatal and postnatal growth.J Clin Endocrinol Metab. 2007; 92: 46
- Adrenarche, pubertal development, age at menarche and final height of fullterm, born small for gestational age (SGA) girls.Gynecol Endocrinol. 2001; 15: 91
- Influence of GnRH analog therapy on body mass in central precocious puberty.Pediatr Endocrinol Diabetes Metab. 2009; 15: 7
- The influence of gonadotropin-releasing hormone agonists on anthropometric change in girls with central precocious puberty.Korean J Pediatr. 2017; 60: 395
- Precocious puberty and body composition: effects of GnRH analog treatment.J Pediatr Endocrinol Metab. 2000; 13: 791
- The effect of gonadotropin- releasing hormone analog treatement (leuprolide) on body fat distribution in idiopathic central precocious puberty.Turk J Pediatr. 2011; 53: 27
- Gonadotropin-releasing hormone agonist therapy and obesity in girls.Int J Endocrinol Metab. 2015; 13: 23085
- Reduction of baseline body mass index under gonadotropin suppressive therapy in girls with idiopathic precocious puberty.Eur J Endocrinol. 2004; 150: 533
- Adult height, body mass index and time of menarche in girls with idiopathic central precocious puberty after gonadotropin releasing hormone analogue treatment.Gynecol Endocrinol. 2011; 27: 524
- The different effects of gonadotropin releasing agonist therapy on body mass index and growth between normal-weight and overweight girls with central precocious puberty.Ann Pediatr Endocrinol Metab. 2017; 2: 49
Published online: January 09, 2019
The authors indicate no conflicts of interest.
Z.H.D. and Z.Y.A. contributed equally to this work.
© 2019 North American Society for Pediatric and Adolescent Gynecology. Published by Elsevier Inc.